The IL-1β Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure

The IL-1β Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure

This study reports preclinical data showing that the interleukin (IL)-1β modulation is a new promising target in the pathophysiological context of heart failure. Indeed, in nondiabetic Wistar and diabetic Goto-Kakizaki rats with chronic heart failure induced by myocardial infarction, administration...

Full description

Bibliographic Details
Main Authors: Najah Harouki, BS, Lionel Nicol, PhD, Isabelle Remy-Jouet, PhD, Jean-Paul Henry, BS, Anais Dumesnil, BS, Annie Lejeune, BS, Sylvanie Renet, BS, Francesca Golding, BS, Zoubir Djerada, PhD, Didier Wecker, PhD, Virginie Bolduc, PhD, Muriel Bouly, PhD, Jerome Roussel, PhD, Vincent Richard, PhD, Paul Mulder, PhD
Format: Article
Language:English
Published: Elsevier 2017-08-01
Series:JACC: Basic to Translational Science
Subjects:
cardiovascular function
heart failure
IL-1β
ischemia/reperfusion
Online Access:http://www.sciencedirect.com/science/article/pii/S2452302X17301511

Internet

http://www.sciencedirect.com/science/article/pii/S2452302X17301511

Similar Items